Josep Ribalta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6644460/publications.pdf

Version: 2024-02-01

172457 168389 2,966 90 29 53 h-index citations g-index papers 97 97 97 4631 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects. Journal of Proteomics, 2022, 251, 104398.	2.4	7
2	Perfil lipoproteico por espectroscopia nuclear magn \tilde{A} ©tica en pacientes con insuficiencia cardiaca cr \tilde{A}^3 nica comparado con controles apareados. Revista Espanola De Cardiologia, 2022, , .	1.2	0
3	Muscular carnosine is a marker for cardiorespiratory fitness and cardiometabolic risk factors in men with type 1 diabetes. European Journal of Applied Physiology, 2022, , 1.	2.5	O
4	Characterization of the LPS and 3OHFA Contents in the Lipoprotein Fractions and Lipoprotein Particles of Healthy Men. Biomolecules, 2022, 12, 47.	4.0	5
5	Low-density lipoprotein from active SLE patients is more atherogenic to endothelial cells than low-density lipoprotein from the same patients during remission. Rheumatology, 2021, 60, 866-871.	1.9	4
6	1H-magnetic resonance spectroscopy lipoprotein profile in patients with chronic heart failure versus matched controls. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	1
7	Statistical mediation of the relationships between chronological age and lipoproteins by nonessential amino acids in healthy men. Computational and Structural Biotechnology Journal, 2021, 19, 6169-6178.	4.1	1
8	Activation of nuclear factor-kappa B subunits c-Rel, p65 and p50 by plasma lipids and fatty acids across the menstrual cycle. Free Radical Biology and Medicine, 2020, 160, 488-500.	2.9	2
9	Precipitated sdLDL: An easy method to estimate LDL particle size. Journal of Clinical Laboratory Analysis, 2020, 34, e23282.	2.1	9
10	Lowâ€density lipoprotein net charge is a risk factor for atherosclerosis in lupus patients independent of lipid concentrations. International Journal of Rheumatic Diseases, 2019, 22, 480-487.	1.9	7
11	La asignación de factor impacto a ClÃnica e Investigación en Arteriosclerosis. Un objetivo cada vez más cercano. ClÃnica E Investigación En Arteriosclerosis, 2019, 31, 261-262.	0.8	O
12	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levelsâ€"The zero-LDL hypothesis. Journal of Clinical Lipidology, 2018, 12, 292-299.e3.	1.5	51
13	LipSpin: A New Bioinformatics Tool for Quantitative ¹ H NMR Lipid Profiling. Analytical Chemistry, 2018, 90, 2031-2040.	6.5	38
14	Progesterone-associated arginine decline at luteal phase of menstrual cycle and associations with related amino acids and nuclear factor kB activation. PLoS ONE, 2018, 13, e0200489.	2.5	14
15	Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact. Current Atherosclerosis Reports, 2017, 19, 30.	4.8	45
16	Differential leucocyte RNA expression in the coronary arteries compared to systemic circulation discriminates between patients with and those without coronary artery disease. ClÃnica E Investigación En Arteriosclerosis, 2017, 29, 60-66.	0.8	2
17	Differential leucocyte RNA expression in the coronary arteries compared to systemic circulation discriminates between patients with and those without coronary artery disease. ClĀnica E Investigación En Arteriosclerosis (English Edition), 2017, 29, 60-66.	0.2	O
18	APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels. Clinical Science, 2016, 130, 2053-2059.	4.3	15

#	Article	IF	CITATIONS
19	Letter to Editor: Increased Presence of Remnant Lipoprotein Cholesterol in The Hdl of Diabetic Subjects. Annals of Clinical and Laboratory Science, 2016, 46, 229-32.	0.2	0
20	Body mass index correlates with atherogenic lipoprotein profile even in nonobese, normoglycemic, and normolipidemic healthy men. Journal of Clinical Lipidology, 2015, 9, 824-831.e1.	1.5	12
21	Polymorphisms in <i>LPL</i> , <i>CETP</i> , and <i>HL</i> Protect HIV-Infected Patients from Atherogenic Dyslipidemia in an Allele-Dose-Dependent Manner. AIDS Research and Human Retroviruses, 2015, 31, 882-888.	1.1	5
22	Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Clinical Science, 2015, 128, 877-882.	4.3	25
23	Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. Journal of Lipid Research, 2015, 56, 737-746.	4.2	133
24	APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis, 2015, 240, 98-104.	0.8	28
25	Design and evaluation of standard lipid prediction models based on 1H-NMR spectroscopy of human serum/plasma samples. Metabolomics, 2015, 11, 1394-1404.	3.0	3
26	Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. Antiviral Research, 2015 , 114 , $48-52$.	4.1	7
27	Improving Assessment of Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy. PLoS ONE, 2015, 10, e0136348.	2.5	10
28	Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients. Lupus, 2014, 23, 245-254.	1.6	29
29	Tissue-specific DNA methylation profiles regulate liver-specific expression of the APOA1/C3/A4/A5 cluster and can be manipulated with demethylating agents on intestinal cells. Atherosclerosis, 2014, 237, 528-535.	0.8	15
30	MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: Effects of treatment with atorvastatin. ClÃnica E Investigación En Arteriosclerosis, 2014, 26, 49-57.	0.8	5
31	Association between lipid genetic and immunological status in chronically HIV-infected patients. Journal of the International AIDS Society, 2014, 17, 19555.	3.0	1
32	Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. Journal of the International AIDS Society, 2014, 17, 19557.	3.0	2
33	Does aging affect the immune status? A comparative analysis in 300 healthy volunteers from France, Austria and Spain. Immunity and Ageing, 2013, 10, 38.	4.2	23
34	Transâ€vessel gradient of myeloperoxidase in coronary artery disease. European Journal of Clinical Investigation, 2013, 43, 920-925.	3.4	14
35	Immune status is more affected by age than by carotenoid depletion–repletion in healthy human subjects. British Journal of Nutrition, 2012, 108, 2054-2065.	2.3	16
36	Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis, 2012, 225, 224-230.	0.8	31

#	Article	IF	CITATIONS
37	APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 756-762.	2.6	33
38	Two Variants in the Fibulin2 Gene Are Associated with Lower Systolic Blood Pressure and Decreased Risk of Hypertension. PLoS ONE, 2012, 7, e43051.	2.5	9
39	Cocoa, Hazelnuts, Sterols and Soluble Fiber Cream Reduces Lipids and Inflammation Biomarkers in Hypertensive Patients: A Randomized Controlled Trial. PLoS ONE, 2012, 7, e31103.	2.5	37
40	Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin. Atherosclerosis, 2011, 215, 125-129.	0.8	7
41	Neutrophils are immune cells preferentially targeted by retinoic acid in elderly subjects. Immunity and Ageing, 2010, 7, 10.	4.2	17
42	Nuclear Magnetic Resonance Lipoprotein Subclasses and the APOE Genotype Influence Carotid Atherosclerosis in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2259-2267.	2.0	20
43	La apolipoproteÃna A-II y las múltiples funciones de la HDL. ClÃnica E Investigación En Arteriosclerosis, 2010, 22, 198-199.	0.8	0
44	The apolipoprotein A5 (APOA5) gene predisposes Caucasian children to elevated triglycerides and vitamin E (Four Provinces Study). Atherosclerosis, 2010, 212, 543-547.	0.8	21
45	Progress in understanding postprandial dyslipidaemia: Second International Symposium on the Role of Chylomicrons in Disease I. Atherosclerosis Supplements, 2010, 11 , 1 -2.	1.2	1
46	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, The, 2010, 375, 1634-1639.	13.7	606
47	The â^'1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: A postprandial study. Atherosclerosis, 2009, 206, 148-152.	0.8	24
48	Prox-1 and FOXC2 gene expression in adipose tissue: A potential contributory role of the lymphatic system to familial combined hyperlipidaemia. Atherosclerosis, 2009, 206, 343-345.	0.8	21
49	Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to shortâ€chain fatty acids. IUBMB Life, 2008, 60, 757-764.	3.4	98
50	Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 380-387.	2.6	45
51	El gen de la apolipoproteÃna A5 se expresa en el intestino humano. ClÃnica E Investigación En Arteriosclerosis, 2008, 20, 129-134.	0.8	1
52	The apolipoprotein A5 gene –1131T→C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. Clinical Chemistry and Laboratory Medicine, 2008, 46, 453-7.	2.3	16
53	Retinoic acid induces PGI synthase expression in human endothelial cells. Journal of Lipid Research, 2008, 49, 1707-1714.	4.2	21
54	Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol. Clinical Chemistry and Laboratory Medicine, 2007, 45, 615-20.	2.3	10

#	Article	IF	Citations
55	Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene â°'1131T>C variant and associations with plasma lipids and lipid peroxidation. Journal of Lipid Research, 2007, 48, 2506-2513.	4.2	20
56	Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray. Clinical Chemistry and Laboratory Medicine, 2007, 45, 829-34.	2.3	3
57	Effects of soluble fiber (Plantago ovatahusk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease. American Journal of Clinical Nutrition, 2007, 85, 1157-1163.	4.7	50
58	Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clinica Chimica Acta, 2007, 384, 141-148.	1.1	76
59	Efecto del ácido 13-cis-retinoico sobre el perfil de expresión génica de células HUVEC (human umbilical) Tj 19, 129-135.	ETQq1 1 0.8	0.784314 rg 0
60	Age-related change in the retinoid X receptor beta gene expression in peripheral blood mononuclear cells of healthy volunteers: Effect of 13-cis retinoic acid supplementation. Mechanisms of Ageing and Development, 2007, 128, 594-600.	4.6	12
61	Familial hypercholesterolemia associated with severe hypoalphalipoproteinemia in a Moroccan family. Journal of Genetics, 2007, 86, 159-163.	0.7	4
62	Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5–1131T→C Gene Variation. Clinical Chemistry, 2006, 52, 1914-1919.	3.2	48
63	In vivo and in vitro evidences that carotenoids could modulate the neutrophil respiratory burst during dietary manipulation. European Journal of Nutrition, 2005, 44, 114-120.	3.9	39
64	Additive Effects of the PPAR \hat{I}^3 , APOE, and FABP-2 Genes in Increasing Daylong Triglycerides of Normolipidemic Women to Concentrations Comparable to Those in Men. Clinical Chemistry, 2005, 51, 864-871.	3.2	15
65	Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study). Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 47-52.	2.1	45
66	The Effect of Age on Vitamin E Status, Metabolism, and Function: Metabolism as Assessed by Labeled Tocopherols. Annals of the New York Academy of Sciences, 2004, 1031, 40-43.	3.8	10
67	Effects of Vitamin E Depletion/Repletion on Biomarkers of Oxidative Stress in Healthy Aging. Annals of the New York Academy of Sciences, 2004, 1031, 361-364.	3.8	18
68	Does Aging Affect the Response of Vitamin E Status to Vitamin E Depletion and Supplementation?. Annals of the New York Academy of Sciences, 2004, 1031, 381-384.	3.8	4
69	Diurnal triglyceridaemia and insulin resistance in mildly obese subjects with normal fasting plasma lipids. Journal of Internal Medicine, 2004, 255, 74-81.	6.0	16
70	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. Aids, 2004, 18, 819-821.	2,2	46
71	Comparison of the postprandial chylomicron carotenoid responses in young and older subjects. European Journal of Nutrition, 2003, 42, 315-323.	3.9	60
72	Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene. Journal of Human Genetics, 2003, 48, 199-203.	2.3	27

#	Article	IF	CITATIONS
73	Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. Molecular Aspects of Medicine, 2003, 24, 391-402.	6.4	65
74	Two novel single nucleotide polymorphisms in the promoter of the Cellular Retinoic Acid Binding Protein II gene (CRABP-II). Molecular and Cellular Probes, 2003, 17, 21-23.	2.1	10
75	The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects. Clinical Chemistry and Laboratory Medicine, 2003, 41, 517-21.	2.3	33
76	Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 177-187.	2.5	51
77	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. Aids, 2002, 16, 1383-1389.	2.2	92
78	Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. Atherosclerosis, 2002, 164, 45-56.	0.8	63
79	Impaired vitamin E status in patients with parenchymal liver cirrhosis: Relationships with lipoprotein compositional alterations, nutritional factors, and oxidative susceptibility of plasma. Metabolism: Clinical and Experimental, 2002, 51, 609-615.	3.4	18
80	Newly Identified Apolipoprotein AV Gene Predisposes to High Plasma Triglycerides in Familial Combined Hyperlipidemia. Clinical Chemistry, 2002, 48, 1597-1600.	3.2	121
81	Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clinical Chemistry, 2002, 48, 1597-600.	3.2	29
82	2,4-Decadienal downregulates TNF- $\hat{l}\pm$ gene expression in THP-1 human macrophages. Atherosclerosis, 2001, 158, 95-101.	0.8	17
83	Antioxidative and Antiatherosclerotic Effects of Human Apolipoprotein A-IV in Apolipoprotein E–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1023-1028.	2.4	131
84	Diurnal triglyceride profiles in healthy normolipidemic male subjects are associated to insulin sensitivity, body composition and diet. European Journal of Clinical Investigation, 2000, 30, 964-971.	3.4	47
85	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. Clinical Chemistry and Laboratory Medicine, 2000, 38, 721-730.	2.3	70
86	ApoCIII Gene Variants Modulate Postprandial Response to Both Glucose and Fat Tolerance Tests. Circulation, 1999, 99, 1872-1877.	1.6	81
87	Vitamin A is linked to the expression of the Al-CIII-AIV gene cluster in familial combined hyperlipidemia. Journal of Lipid Research, 1999, 40, 426-431.	4.2	9
88	Evidence against alterations in Lecithin:cholesterol acyltransferase (LCAT) activity in Familial combined hyperlipidemia. Atherosclerosis, 1998, 138, 383-389.	0.8	3
89	Low plasma vitamin A concentrations in familial combined hyperlipidemia. Clinical Chemistry, 1997, 43, 2379-2383.	3.2	7
90	Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. Cardiovascular Drugs and Therapy, 1997, 11, 653-658.	2.6	7